Solène Guilliot, PharmD/PhD

JAD profile

Associate Editor

Term Expiration: 

12/31/2024

Affiliation(s): 

Medesis Pharma

Areas of Interest: 

AD: Alzheimer Disease, Alzheimer's disease; neurodegeneration; amyloid; tau; tauopathy, Aging and Cognition; Dementia; Cognitive Impairment; neurodegenerative disease, Alzheimer's & oxidative Stress, Aging and Cognition; Dementia; Alzheimer; Neuropsychological assessment

Biography & Research: 

Solène Guilliot is a Doctor of Pharmacy with over 7 years of experience in global medical affairs and clinical development. Trained in Neurology at Toronto North York General Hospital, she has extensive experience in global drug development and medical affairs management in neurology (neurodegenerative diseases), auto-immune diseases and RNA-based therapeutics. Previously, she held several international positions at Sanofi Genzyme and Bristol-Myers Squibb (USA, Canada, Germany and France). She joined Medesis Pharma in 2021 and undertook the conduct of the Nanoli-AD clinical trial. Poster. S. Guilliot ; A. Mouri ; J-C. Maurel. Gene Therapy for Neurological Disorders. Dec. 6th-9th 2021. Aonys® ensures siRNA delivery for gene silencing in neurodegenerative diseases • Poster (P169) : M. Soto, , S. Guiliot, , P.J. Ousset, , D. Angioni, , N. Sastre, Hengan, J.C. Maurel, , J. Touchon. A proof-of-concept study to evaluate efficacy ofnanolithium on the progression of neuropsychiatric symptoms in patients with mild-to-severe alzheimer’s disease. 15TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE Conference. San Francisco, CA (USA). Nov 29th – Dec. 2nd 2022. • Poster: S. Guilliot ; A. Mouri ; A. Relano-Gines; J-C. Maurel. RNA Leaders. March 15th-16th 2023. Aonys® technology - Buccal administration for siRNA systemic delivery • Poster: Maria Soto, Solène Guilliot, Pierre-Jean Ousset, Karim Bennys, Claire Paquet, Jacques Touchon, Edward N. Wilson. 16TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE Conference. Boston, MA (USA). October 24th – Oct. 27nd 2022: Nanolithium has a dual potential in Alzheimer’s disease: to treat NPS and modify disease course. • Manuscript in review: S. Guilliot, E. N. Wilson, J. Touchon, M. E. Soto. JPAD. Nanolithium, a new treatment approach to Alzheimer’s disease: a review of existing evidence, and discussion and clinical perspectives of the treatment landscape. • Manuscript - JAD: S. Guilliot, S. Gauthier, J. Touchon, M. E. Soto. Lithium, a treatment option for Alzheimer’s disease? A review of existing evidence and discussion on future perspectives.